Amorphous active pharmaceutical ingredients in preclinical studies: Preparation, characterization, and formulation

Current Bioactive Compounds

Volumn 4, Issue 4, 2008, Pages 213-224

  Nagapudi, Karthik ^a   Jona, Janan ^a  

^a AMGEN INC   (United States)

Author keywords

Amorphous pharmaceuticals; Crystallization; Preclinical; Solid dispersions

Indexed keywords

CHITOSAN; COPOLYMER; DRUG CARRIER; ETHYLENE GLYCOL; FLUCONAZOLE; HYDROXYPROPYLMETHYLCELLULOSE; HYDROXYPROPYLMETHYLCELLULOSE ACETATE SUCCINATE; MACROGOL; NATURAL PRODUCT; PIROXICAM; POLY(VINYL PYRROLIDONE CO VINYL ACETATE); POLYACRYLIC ACID; POLYMER; POLYVINYL ALCOHOL; POVIDONE; PROPYLENE GLYCOL; RITONAVIR; UNCLASSIFIED DRUG;

ANALYTIC METHOD; COMBINATORIAL CHEMISTRY; CRYSTAL STRUCTURE; CRYSTALLIZATION; DISSOLUTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG PURIFICATION; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; DRUG SOLUBILITY; DRUG STABILITY; DRUG SYNTHESIS; ENTROPY; FREEZE DRYING; HIGH TEMPERATURE PROCEDURES; MISCIBILITY; MOLECULAR INTERACTION; PHYSICAL CHEMISTRY; PRECIPITATION; PRIORITY JOURNAL; RAMAN SPECTROMETRY; REVIEW; SEPARATION TECHNIQUE; THERMODYNAMICS;

EID: 65649097313     PISSN: 15734072     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340708786847852     Document Type: Review

References (75)

1. Amidon, G.L., Lennernaes, H., Shah, V.P., Crison, J.R. (1995) A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res., 12, 413-420.
2. Takagi, T., Ramachandran, C., Bermejo, M., Yamashita, S., Yu, L.X., Amidon, G.L. (2006) A Provisional Biopharmaceutical Classification of the Top 200 Oral Drug Products in the United States, Great Britain, Spain, and Japan. Mol. Pharm., 3, 631-643.
3. Neervannan, S. (2006) Preclinical formulations for discovery and toxicology: Physicochemical challenges. Expert Opin. Drug Metab. Toxicol., 2, 715-731.
4. Hancock, B.C., Parks, M. (2000) What is the true solubility advantage for amorphous pharmaceuticals? Pharm. Res., 17, 397-404.
5. Bhugra, C., Pikal, M.J. (2008) Role of thermodynamic, molecular, and kinetic factors in crystallization from the amorphous state. J. Pharm. Sci., 97, 1329-1349.
6. Craig, D.Q., Royall, P.G., Kett, V.L., Hopton, M.L. (1999) The relevance of the amorphous state to pharmaceutical dosage forms: Glassy drugs and freeze dried systems. Int. J. Pharm., 179, 179-207.
7. Hancock, B.C., Zografi, G. (1997) Characteristics and significance of the amorphous state in pharmaceutical systems. J. Pharm. Sci., 86, 1-12.
8. Hilden, L.R., Morris, K.R. (2004) Physics of amorphous solids. J. Pharm. Sci., 93, 3-12.
9. Yu, L. (2001) Amorphous pharmaceutical solids: Preparation, characterization and stabilization. Adv. Drug Deliv. Rev., 48, 27-42.
10. Marsac, P.J., Konno, H., Rumondor, A.C.F., Taylor, L.S. (2008) Recrystallization of nifedipine and felodipine from amorphous molecular level solid dispersions containing poly(vinylpyrrolidone) and sorbed water. Pharm. Res., 25, 647-656.
11. Marsac, P.J., Konno, H., Taylor, L.S. (2006) A comparison of the physical stability of amorphous felodipine and nifedipine systems. Pharm. Res., 23, 2306-2316.
12. Miyazaki, T., Yoshioka, S., Aso, Y., Kawanishi, T. (2007). Crystallization rate of amorphous nifedipine analogues unrelated to the glass transition temperature. Int. J. Pharm., 336, 191-195.
13. Shakhtshneider, T.P., Danede, F., Capet, F., Willart, J.F., Descamps, M., Myz, S.A., Boldyreva, E.V., Boldyrev, V.V. (2007) Grinding of drugs with pharmaceutical excipients at cryogenic temperatures. Part I. Cryogenic grinding of piroxicam-polyvinylpyrrolidone mixtures. J. Therm. Anal. Calorim., 89, 699-707.
14. Shakhtshneider, T.P., Danede, F., Capet, F., Willart, J.F., Descamps, M., Paccou, L., Surov, E.V., Boldyreva, E.V., Boldyrev, V.V. (2007) Grinding of drugs with pharmaceutical excipients at cryogenic temperatures. Part II. Cryogenic grinding of indomethacin-polyvinylpyrrolidone mixtures. J. Therm. Anal. Calorim., 89, 709-715.
15. Descamps, M., Willart, J.F., Dudognon, E., Caron, V. (2007) Transformation of pharmaceutical compounds upon milling and comilling: the role of Tg. J. Pharm. Sci., 96, 1398-1407.
16. Li, Y., Han, J., Zhang, G.G.Z., Grant, D.J.W., Suryanarayanan, R. (2000) In situ dehydration of carbamazepine dihydrate: A novel technique to prepare amorphous anhydrous carbamazepine. Pharm. Dev. Technol., 5, 257-266.
17. Saleki-Gerhardt, A., Stowell, J.G., Byrn, S.R., Zografi, G. (1995) The hydration and dehydration of crystalline and amorphous forms of raffinose. J. Pharm. Sci., 84, 318-323.
18. Broadhead, J., Rouan, S.K.E., Rhodes, C.T. (1992) The spray drying of pharmaceuticals. Drug Dev. Ind. Pharm., 18, 1169-1206.
19. Vasanthavada, M., Tong, W.-Q., Joshi, Y., Kislalioglu, M.S. (2004). Phase behavior of amorphous molecular dispersions I: Determination of the degree and mechanism of solid solubility. Pharm. Res., 21, 1598-1606.
20. Alvarez-Nunez, F.A., Leonard, M.R. (2004) Formulation of a poorly soluble drug using hot melt extrusion: The amorphous state as an alternative. Am. Pharm. Rev., 7, 88-92.
21. Shah, B., Kakumanu, V.K., Bansal, A.K. (2006) Analytical techniques for quantification of amorphous/crystalline phases in pharmaceutical solids. J. Pharm. Sci., 95, 1641-1665.
22. Chen, X., Bates, S., Morris, K.R. (2001) Quantifying amorphous content of lactose using parallel beam X-ray powder diffraction and whole pattern fitting. J. Pharm. Biomed. Anal., 26, 63-72.
23. Iyengar, S.S., Phadnis, N.V., Suryanarayanan, R. (2001) Quantitative analyses of complex pharmaceutical mixtures by the Rietveld method. Powder Diffr., 16, 20-24.
24. Nunes, C., Mahendrasingam, A., Suryanarayanan, R. (2005) Quantification of crystallinity in substantially amorphous materials by synchrotron X-ray powder diffractometry. Pharm. Res., 22, 1942-1953.
25. Surana, R., Suryanarayanan, R. (2000) Quantitation of crystallinity in substantially amorphous pharmaceuticals and study of crystallization kinetics by X-ray powder diffractometry. Powder Diffr., 15, 2-6.
26. Giron, D., Goldbronn, C. (1997) Use of DSC and TG for the identification and quantification of the dosage form. J. Therm. Anal. Calorim., 48, 473-483.
27. Lefort, R., De Gusseme, A., Willart, J.F., Danede, F., Descamps, M. (2004) Solid state NMR and DSC methods for quantifying the amorphous content in solid dosage forms: An application to ball-milling of trehalose. Int. J. Pharm., 280, 209-219.
28. Vitez, I.M. (2004) Utilization of DSC for pharmaceutical crystal form quantitation. J. Therm. Anal. Calorim., 78, 33-45.
29. Lappalainen, M., Pitkaenen, I. (2006) Quantification of amorphous content in maltitol. J. Therm. Anal. Calorim., 84, 345-353.
30. Saklatvala, R., Royall, P.G., Craig, D.Q.M. (1999) The detection of amorphous material in a nominally crystalline drug using modulated temperature DSC. A case study. Int. J. Pharm., 192, 55-62.
31. Brown, S.C., Claybourn, M., Fawcett, V., Rodger, C. (2007) Optimizing raman spectroscopy to quantify polymorphic forms of a drug molecule. Am. Pharm. Rev., 10, 58, 60-67.
32. Head, T., Rydzak, J. (2003) Chemometric models using diamond attenuated total reflectance IR and Raman spectroscopy to characterize and quantitate polymorphs in pharmaceuticals. Am. Pharm. Rev., 6, 78-84.
33. Luner, P.E., Majuru, S., Seyer, J.J., Kemper, M.S. (2000) Quantifying crystalline form composition in binary powder mixtures using near-infrared reflectance spectroscopy. Pharm. Dev. Technol., 5, 231-246.
34. Strachan, C.J., Rades, T., Gordon, K.C., Rantanen, J. (2007) Raman spectroscopy for quantitative analysis of pharmaceutical solids. J. Pharm. Pharmacol., 59, 179-192.
35. Offerdahl, T.J., Salsbury, J.S., Dong, Z., Grant, D.J.W., Schroeder, S.A., Prakash, I., Gorman, E.M., Barich, D.H., Munson, E.J. (2005) Quantitation of crystalline and amorphous forms of anhydrous neotame using 13C CPMAS NMR spectroscopy. J. Pharm. Sci., 94, 2591-2605.
36. Venkatesh, G.M., Barnett, M.E., Owusu-Fordjour, C., Galop, M. (2001) Detection of low levels of the amorphous phase in crystalline pharmaceutical materials by thermally stimulated current spectrometry. Pharm. Res., 18, 98-103.
37. Farrer, B.T., Peresypkin, A., Wenslow, R.M. (2006) Quantitation of crystalline material within a liquid vehicle using 1H/19F CP/MAS NMR. J. Pharm. Sci., 96, 264-267.
38. Siniti, M., Carre, J., Letoffe, J.M., Bastide, J.P., Claudy, P. (1993) the thermal behavior of hexitols. Part 1. Vitrification and crystallization of iditol, mannitol, sorbitol, and dulcitol. Thermochim. Acta, 224, 97-104.
39. Zhou, D., Zhang, G.G.Z., Law, D., Grant, D.J.W., Schmitt, E.A. (2002) Physical stability of amorphous pharmaceuticals: Importance of configurational thermodynamic quantities and molecular mobility. J. Pharm. Sci., 91, 1863-1872.
40. Carpentier, L., Desprez, S., Descamps, M. (2003) Crystallization and glass properties of pentitols. Xylitol, adonitol, arabitols. J. Therm. Anal. Calorim., 73, 577-586.
41. Andronis, V., Zografi, G. (2000) Crystal nucleation and growth of indomethacin polymorphs from the amorphous state. J. Non-Cryst. Solids, 271, 236-248.
42. Sheth, A.R., Bates, S., Muller, F.X., Grant, D.J.W. (2004) Polymorphism in Piroxicam. Cryst. Growth Des., 4, 1091-1098.
43. Sheth, A.R., Bates, S., Muller, F.X., Grant, D.J.W. (2005) Local structure in amorphous phases of piroxicam from powder X-ray diffractometry. Cryst. Growth Des., 5, 571-578.
44. Hodge, I.M. (1996) Strong and fragile liquids - a brief critique. J. Non-Cryst. Solids, 202, 164-172.
45. Shmeis, R.A., Wang, Z., Krill, S.L. (2004) A mechanistic investigation of an amorphous pharmaceutical and its solid dispersions, Part II: Molecular mobility and activation thermodynamic parameters. Pharm. Res., 21, 2031-2039.
46. Tanaka, K., Kitamura, S., Koda, S. (2000) The relationship between solid-state stability and molecular mobility below glass transition temperature of amorphous pharmaceutical solids. Pharm. Tech. Jpn., 16, 1881-1890.
47. Hancock, B.C., Shamblin, S.L., Zografi, G. (1995) Molecular mobility of amorphous pharmaceutical solids below their glass transition temperatures. Pharm. Res., 12, 799-806.
48. Aso, Y., Yoshioka, S., Kojima, S. (2001) Explanation of the crystallization rate of amorphous nifedipine and phenobarbital from their molecular mobility as measured by 13C nuclear magnetic resonance relaxation time and the relaxation time obtained from the heating rate dependence of the glass transition temperature. J. Pharm. Sci., 90, 798-806.
49. Aso, Y., Yoshioka, S., Kojima, S. (2004) Molecular mobility-based estimation of the crystallization rates of amorphous nifedipine and phenobarbital in poly(vinylpyrrolidone) solid dispersions. J. Pharm. Sci., 93, 384-391.
50. Bhugra, C., Shmeis, R., Krill, S.L., Pikal, M.J. (2006) Predictions of onset of crystallization from experimental relaxation times I-correlation of molecular mobility from temperatures above the glass transition to temperatures below the glass transition. Pharm. Res., 23, 2277-2290.
51. Bhugra, C., Shmeis, R., Krill, S.L., Pikal, M.J. (2006) Predictions of onset of crystallization from experimental relaxation times II-comparison between predicted and experimental onset times. J. Pharm. Sci., 97, 455-472.
52. Carpentier, L., Decressain, R., Gusseme, A., Neves, C., Descamps, M. (2006) Molecular mobility in glass forming fananserine: A dielectric, NMR, and TMDSC investigation. Pharm. Res., 23, 798-805.
53. Vyazovkin, S., Dranca, I. (2007) Effect of physical aging on nucleation of amorphous indomethacin. J. Phys. Chem. B, 111, 7283-7287.
54. Vyazovkin, S., Dranca, I. (2006) Probing beta relaxation in pharmaceutically relevant glasses by using DSC. Pharm. Res., 23, 422-428.
55. Wu, T., Yu, L. (2006) Surface crystallization of indomethacin below Tg. Pharm. Res., 23, 2350-2355.
56. Surana, R., Pyne, A., Suryanarayanan, R. (2004) Effect of preparation method on physical properties of amorphous trehalose. Pharm. Res., 21, 1167-1176.
57. Konno, H., Taylor, L.S. (2006) Influence of different polymers on the crystallization tendency of molecularly dispersed amorphous felodipine. J. Pharm. Sci., 95, 2692-2705.
58. Yoshihashi, Y., Iijima, H., Yonemochi, E., Terada, K. (2006) Estimation of physical stability of amorphous solid dispersion using differential scanning calorimetry. J. Therm. Anal. Calorim., 85, 689-692.
59. Vasanthavada, M., Tong, W.-Q., Joshi, Y., Kislalioglu, M.S. (2005) Phase behavior of amorphous molecular dispersions. II: Role of hydrogen bonding in solid solubility and phase separation kinetics. Pharm. Res., 22, 440-448.
60. Fedors, R.F. (1974) Method for estimating both the solubility parameters and molar volumes of liquids. Polym. Eng. Sci., 14, 147-154.
61. Forster, A., Hempenstall, J., Tucker, I., Rades, T. (2001) Selection of excipients for melt extrusion with two poorly water-soluble drugs by solubility parameter calculation and thermal analysis. Int. J. Pharm., 226, 147-161.
62. Greenhalgh, D.J., Williams, A.C., Timmins, P., York, P. (1999) Solubility parameters as predictors of miscibility in solid dispersions. J. Pharm. Sci., 88, 1182-1190.
63. Theeuwes, F., Hussain, A., Higuchi, T. (1974) Quantitative analytical method for determination of drugs dispersed in polymers using differential scanning calorimetry. J. Pharm. Sci., 63, 427-429.
64. Mohan, R., Lorenz, H., Myerson, A.S. (2002) Solubility measurement using differential scanning calorimetry. Ind. Eng. Chem. Res., 41, 4854-4862.
65. Marsac, P.J., Shamblin, S.L., Taylor, L.S. (2006) Theoretical and practical approaches for prediction of drug-polymer miscibility and solubility. Pharm. Res., 23, 2417-2426.
66. Gordon, M., Taylor, J.S. (1952) Ideal copolymers and the second-order transitions of synthetic rubbers. I. Noncrystalline copolymers. J. Appl. Chem., 2, 493-500.
67. Couchman, P.R., Karasz, F.E. (1978) A classical thermodynamic discussion of the effect of composition on glass-transition temperatures. Macromolecules, 11, 117-119.
68. Schneider, H.A. (1997) Conformational entropy contributions to the glass temperature of blends of miscible polymers. J. Res. Natl. Inst. Stand. Technol., 102, 229-248.
69. Qiu, L.Y., Bae, Y.H. (2006) Polymer architecture and drug delivery. Pharm. Res., 23, 1-30.
70. Kinoshita, M., Baba, K., Nagayasu, A., Yamabe, K., Azuma, M., Houchi, H., Minakuchi, K. (2003) Highly stabilized amorphous 3-bis(4-methoxyphenyl)methylene-2-indolinone (TAS-301) in melt-adsorbed products with silicate compounds. Drug Dev. Ind. Pharm., 29, 523-529.
71. Bahl, D., Hudak, J., Bogner, R.H. (2008) Comparison of the ability of various pharmaceutical silicates to amorphize and enhance dissolution of indomethacin upon co-grinding. Pharm. Dev. Technol., 13, 255-269.
72. Bahl, D., Bogner, R.H. (2006) Amorphization of indomethacin by co-grinding with neusilin US2: Amorphization kinetics, physical stability and mechanism. Pharm. Res., 23, 2317-2325.
73. Law, D., Schmitt, E.A., Marsh, K.C., Everitt, E.A., Wang, W., Fort, J.J., Krill, S.L., Qiu, Y. (2004) Ritonavir-PEG 8000 amorphous solid dispersions: in vitro and in vivo evaluations. J. Pharm. Sci., 93, 563-570.
74. Tantishaiyakul, V., Kaewnopparat, N., Ingkatawornwong, S. (1999) Properties of solid dispersions of piroxicam in polyvinylpyrrolidone. Int. J. Pharm., 181, 143-151.
75. Papageorgiou, G.Z., Bikiaris, D., Kanaze, F.I., Karavas, E., Stergiou, A., Georgarakis, E. (2008) Tailoring the release rates of fluconazole using solid dispersions in polymer blends. Drug Dev. Ind. Pharm., 34, 336-346.